Beta Delta

'When There's Blood in the Streets', Buy Biotech Stocks

ohad.. have you ever followed a small cap biotech named Genvec. Genvec is waiting for their interim peek at the data, which should be released in november.

A Biotech Bloom in July

option dragon.. you should look into immunogen .. imgn and dna have a drug in multiple phase 2 trials and soon a phase 3 trial, trastuzumab-dm1 for metastatic breast cancer. it kills all previous data for herceptin in trials, and may be one of the drivers for Roche wanting a deal for genentech.Herceptin has sales of 4.5 billion worldwide and its very likely that trastuzumab-dm1 may encroach on those sales as genentech much pay a royalty to immunogen on the sales of the new drug.